Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.55 |
| ▸ | PDE4A | P27815 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.55 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.55 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.55 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868224 | 0.85 | TP53 (0.67) | ALDH1A1 | |
| SCHEMBL8293198 | 0.84 | TP53 (0.71) | MEN1ALDH1A1KMT2AL3MBTL1AGTR1 | |
| SCHEMBL25146364 | 0.83 | TP53 (0.65) | ALDH1A1 | |
| SCHEMBL7348851 | 0.82 | MEN1 (0.65) | MEN1ALDH1A1KMT2AL3MBTL1AGTR1 | |
| SCHEMBL8451192 | 0.81 | MEN1 (0.62) | MEN1ALDH1A1KMT2AL3MBTL1AGTR1 | |
| SCHEMBL13197069 | 0.79 | ALDH1A1 (0.59) | MEN1ALDH1A1KMT2AL3MBTL1AGTR1 | |
| Methylbiphenyl Tetrazole SCHEMBL8171721 | 0.79 | MEN1 (0.69) | MEN1ALDH1A1KMT2AL3MBTL1AGTR1 | |
| SCHEMBL30153550 | 0.78 | MEN1 (0.80) | MEN1ALDH1A1KMT2AL3MBTL1GP6 | |
| SCHEMBL8783081 | 0.78 | MEN1 (0.80) | MEN1ALDH1A1KMT2AL3MBTL1GP6 | |
| SCHEMBL13287110 | 0.75 | AGTR1 (0.54) | AGTR1AGTR2GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728024-B2 | Metal salts of 2′-(1H-Tetrazol-5yl)-1.1′-biphenyl-4-carboxaldehyde | NOVARTIS AG (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20080234490-A1 | Metal Salts of 2' - (1H-Tetrazol-5Yl) -1. 1'-Biphenyl-4-Carboxaldehyde | NOVARTIS PHARMACEUTICALS CORPORATION | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234490-A1 | Metal Salts of 2' - (1H-Tetrazol-5Yl) -1. 1'-Biphenyl-4-Carboxaldehyde | REN, AGT, AGTR1 | MEN1 313/4885ALDH1A1 315/4885KMT2A 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.